The Application of an Institutional Clinical Data Warehouse to the Assessment of Adverse Drug Reactions (ADRs)

Summary

Objectives: To apply an institutional clinical data warehouse (CDW) to the assessment of adverse drug reactions (ADRs) and demonstrate its utility through a specific example.

Methods: We modeled the process for assessing ADRs through retrospective cohort design by using CDW at the Osaka University Hospital as follows: 1) We defined a drug X, an adverse drug reaction (ADR) Y, and a laboratory measurement Z to assess Y during a given study period; 2) we excluded those whose Z value exceeded the defined criteria or were not available at the inception of the cohort; 3) we divided the patients into two groups based on exposure or non-exposure to X; 4) we matched the patient characteristics between the two groups through stratification and randomization; and 5) we compared the frequency of patients who presented Y during the study period between the two groups. Aminoglycoside and Cephalosporin associated nephrotoxicity in pediatric inpatients was used as an example to demonstrate the usefulness of this approach.

Results: Our evaluation indicates that there is an increased risk of nephrotoxicity for pediatric inpatients who were prescribed cephalosporin either alone or in combination with aminoglycoside; further, aminoglycoside tends to increase the cephalosporin-associated nephrotoxicity.

Conclusions: Our findings are consistent with those drawn from other studies, indicating thatthe method of a pplying an institutional CDW is useful for assessing ADRs.

Keywords

Clinical data warehouse - relational database - retrospective cohort study - adverse drug reactions

• References

• 1 Weiss ME. Recognizing drug allergy. How to differentiate true allergy from other adverse drug reactions. Postgrad Med 2005; 117 (05) 32-36 39.
• 2 Lazarou J. et al. Incidence of adverse drug reactions in hospitalized patients. JAMA 1998; 279: 1200-1205.
• 3 Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356 (9237): 1255-1259.
• 4 Grahame-Smith DG, Aronson JK. Adverse drug reactions. The Oxford textbook of clinical pharmacology and drug therapy.. Oxford: Oxford University Press; 1984: 132-157.
• 5 Mona Okasha. Epidemiological Research. Student BMJ 2001; 9: 261-304. 0966-6494.
• 6 Jones JK, Staffa J. Estimation of the frequency of warfarin-associated necrosis in a large in-patient record-linked database. Pharmacoepidemiol Drug Saf 1993; 2: 115-126.
• 7 Gardner RM. et al. The HELP hospital information system: update 1998. Int J Med Inform 1999; 54: 169-182.
• 8 Jha AK. et al. Identifying adverse drug events: development of a computer-basedmonitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 1998; 5: 305-314.
• 9 McDonald CJ. et al. The Regenstrief Medical Record System: a quarter century experience. Int J Med Infom 1999; 54: 225-253.
• 10 Lamoreaux J. The organizational structure for medical information management in the department of veterans affairs: an overview of major healthcare databases. Med Care 1996; 34: 31-44.
• 11 Graber SE. et al. Development of a replicated database of DHP data for evaluation of drug use. J Am Med Infom Assoc 1996; 3: 149-156.
• 12 Gaus W. et al. Identification of adverse drug reactions by evaluation of a prescription database, demonstrated for “risk of bleeding”. Methods Inf Med 2005; 44 (05) 697-703.
• 13 Wisniewski MF. et al. Development of a clinical data warehouse for hospital infection control. J Am Med Inform Assoc 2003; 10 (05) 454-462. Epub 2003 Jun 04.
• 14 Yamamoto Y. et al. Development of a time-oriented data warehouse based on amedical information event model. Igaku Butsuri 2002; 22 (04) 327-333.
• 15 Schubart JR, Einbinder JS. Evaluation of a data warehouse in an academic health sciences center. Int J Med Inform 2000; 60 (03) 319-333.
• 16 Ebidia A. et al. Getting data out of the electronic patient record: critical steps in building a data warehouse for decision support. Proc AMIA Symp. 1999: 614-618.
• 17 Lyman JA. et al. Mapping from a clinical data warehouse to the HL7 Reference Information Model. AMIA Annu Symp Proc. 2003: 920.
• 18 Lieberman MI. et al. The use of SNOMED CT simplifies querying of a clinical data warehouse. AMIA Annu Symp Proc. 2003: 910.
• 19 Grant A. et al. Integrating feedback from a clinical datawarehouse into practice organization. Int J Med Inform 2006; 75 3-4 232-239. Epub2005 Sep 8.
• 20 Gray GW. Challenges of building clinical data analysis solutions. J Crit Care 2004; 19 (04) 264-270.
• 21 Scheese R. Data warehouse as a healthcare business solution. Health Finance Manage 1998; 52 (02) 56-59.
• 22 Palevich RF. Supply chain management. Hosp Mater Manage Q 1999; 20 (03) 54-63.
• 23 Yoong SL. Casemix reimbursement: a Singapore Children’s Hospital perspective. Ann Acad Med Singapore 2001; 30 (Suppl. 04) 26-40.
• 24 Bates DW. et al. Using information systems to measure and improve quality. Int J Med Inform 1999; 53 2-3 115-124.
• 25 Lyman JA. et al. Integrating quality assessment tool into a clinical data warehouse. Medinfo. 2004 2004(CD): 1735.
• 26 Koprowski Jr Sp, Barrett JS. Data warehouse implementation with clinical pharmacokinetic/pharmacodynamic data. Int J Clin Pharmacol Ther 2002; 40 (03) S14-29.
• 27 The Chicago Antimicrobial Resistance Project. Available at: http://www.hektoen.org/grants_antimicrobial.htm. Access at 2005/7/13.
• 28 Stephen R. et al. Feasibility of using a large Clinical Data Warehouse to automate the selection of diagnostic cohorts. AMIA Annu Symp Proc. 2003: 1019.
• 29 Wong ST. et al. A Neuroinformatics database system for disease-oriented neuroimaging research. Acad Radiol 2004; 11 (03) 345-358.
• 30 Servais H. et al. Antibiotic-induced nephrotoxicity In: Toxicology of the Kidney (chapter of book). In press.
• 31 Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy 2006; 26 (05) 601-608.
• 32 Kalman D, Barriere SL. Review of the Pharmacology, Pharmacokinetics, and Clinical Use of Cephalosporins. Texas Heart Institute Journal 1990; 17 (03) 203-211.
• 33 Zhanel GG. Cephalosporin-inducednephrotoxicity: does it exist?. DICP 1990; 24 (03) 262-265.
• 34 Rankin GO, Sutherland CH. Nephrotoxicity of aminoglycosides and cephalosporins in combination. Adverse Drug React Acute Poisoning Rev 1989; 8 (02) 73-88.
• 35 Agarwal G. et al. Comparison of once-daily versus twice daily gentamicin dosing regimens in infants >or=2500g. J Perinatol 2002; 22: 268-274.
• 36 Ariffin H. et al. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer. J Paediatr Child Health 2001; 37: 38-43.
• 37 Carapetis JR. et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatr Infect Dis J 2001; 20: 240-246.
• 38 Charnas R. et al. Writing Committee for International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children: once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Pediatr Infect Dis J 1997; 16: 346-353.
• 39 Chong CY. et al. Treatment of urinary tract infection with gentamicin once or three times daily. Acta Paediatr 2003; 92: 291-296.
• 40 Chotigeat U. et al. Gentamicin in neonatal infection: one versus twice daily dosage. J Med Assoc Thai 2001; 84: 1109-1115.
• 41 Contopoulos-Ioannidis DG. etal. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004; 114 (01) e111-118.
• 42 Master V. et al. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: apreliminarystudy. Pediatr Pulmonol 2001; 31: 367-376.
• 43 Uijtendaal EV. et al. Once-daily versus multiple daily gentamicin in infants and children. Ther Drug Monit 2001; 23: 506-513.
• 44 Matsumura Y. et al. Implementation of the totally integrated hospital information system (Humane) in Osaka University Hospital. Medinfo 1995; 8 Pt 1: 590-593.
• 45 Matsumura Y. et al. Dynamic viewer of medical events in electronic medical record. Medinfo 2001; 10 (Pt 1): 648-652.
• 46 Takeda H. et al. A Japanese approach to establish an electronic patient record system in an intelligent hospital. Int J Med Inform 1998; 49 (01) 45-51.
• 47 Matsumura Y. Constructing a Clinical Data Warehouse. BME 2002; 16 (04) 18-23. (In Japanese.).
• 48 Sano K. et al. Evaluation of the diabetes epidemiology by the data warehouse ofa hospital information system. Japanese Journal of Medical Informatics 2001; 21 (02) 161-171.
• 49 Takeda H. et al. Healthcare quality management by means of an incident report system and an electronic patient record system. In J Med Inform 2003; 69 2-3 285-293.
• 50 Zhenjun Y. et al. Similar Cases Retrieval from the Database of Laboratory Test Results. Journal of Medical Systems 2003; 27 (03) 271-282.
• 51 Chen Y. et al. Analysis of yearly variations in drug expenditure for one patient using data warehouse in ahospital. Comput Methods Programs Biomed. 2006 (Epub ahead of print.).
• 52 Calandra T. et al. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily dose of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-593.
• 53 Marik PE. et al. A prospective randomized study comparing once-versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28: 753-764.
• 54 Vigano A. et al. Comparison of 5 milligrams ofnetilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of Gram-negative pyelonephritis in children. Antimicrob Agents Chemother 1992; 36: 1499-1503.
• 55 Cameron J, Greger R. Renal function and testing of function. Davision A. et al. Oxford textbook of clinical nephrology.. 2nd ed. Oxford: Oxford medical Publications; 1998
• 56 Wood PJ. et al. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996; 51: 369-373.
• 57 Lerner AM. et al. Randomised, controlled trial of the comparative efficacy, auditory toxicity and nephrotoxicity of tobramycin and netilmicin. Lancet. 1983: 1123-1126.